Loading clinical trials...
Loading clinical trials...
An Open-Label Treatment Protocol to Provide Continued ACH-126,443 to Subjects of Previous Achillion-Sponsored Phase 1 and 2 Studies in Chronic Hepatitis B Infection
Conditions
Interventions
ACH-126, 443 (beta-L-Fd4C)
Completion Date
May 1, 2003
Last Updated
August 19, 2009
NCT06671093
NCT06885710
NCT06263959
NCT06295328
NCT02883647
NCT04139850
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions